Atrial Fibrillation Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Atrial Fibrillation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion), By End-use (Hospital, Specialty Clinics, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Atrial Fibrillation Market is poised for significant growth, projected to expand from USD 22.61 Billion in 2025 to USD 35.34 Billion by 2031, achieving a CAGR of 7.73%. This market encompasses various medical devices and pharmaceutical treatments for diagnosing, managing, and treating irregular cardiac rhythms, including electrophysiology ablation catheters, diagnostic mapping systems, and left atrial appendage closure devices. Key growth drivers include an expanding geriatric population and the increasing global prevalence of chronic conditions like hypertension and obesity, which elevate arrhythmia risk. For instance, in 2025, the UK recorded 1.62 million atrial fibrillation diagnoses, highlighting the growing clinical need. However, a major impediment to market expansion is the high cost of advanced electrophysiology procedures and ongoing disease management, leading to stringent reimbursement policies and restricted patient access, particularly in cost-sensitive healthcare systems and emerging markets.
Market Driver
The market is significantly driven by the advent of Pulsed Field Ablation (PFA) systems, which offer a safer and more efficient non-thermal alternative to traditional ablation techniques. PFA's ability to selectively ablate myocardial tissue while protecting surrounding structures has led to reduced procedural times and rapid adoption by electrophysiologists for various atrial fibrillation cases. Boston Scientific's Farapulse PFA system, for example, generated $1 billion in revenue within its first year, demonstrating this technological shift. Furthermore, the rising prevalence of cardiovascular comorbidities, such as hypertension and obesity, greatly expands the patient population needing interventions. With approximately 127.9 million U.S. adults affected by some form of cardiovascular disease in 2025, the demand for scalable atrial fibrillation management solutions is intensifying, leading to strong growth for manufacturers, as evidenced by Johnson & Johnson's cardiology division's 22.3% growth in Q2 2025.
Market Challenge
A significant impediment to the Global Atrial Fibrillation Market's expansion is the considerable cost of advanced electrophysiology procedures and ongoing disease management. Procedures like catheter ablation and left atrial appendage closure demand substantial investment in specialized equipment and infrastructure, leading healthcare payers to impose strict reimbursement policies that limit patient access. This financial barrier often slows the adoption of new medical technologies, particularly in cost-sensitive healthcare systems and emerging economies. The economic strain is compounded by the long-term expenses of chronic care, including lifelong anticoagulation and continuous monitoring. With the annual cost of managing atrial fibrillation in the UK estimated to surpass £2.4 billion in 2025, this fiscal burden drives restrictive purchasing policies that hinder overall market development.
Market Trends
Two key trends are shaping the atrial fibrillation market: the growing utilization of Left Atrial Appendage Closure Devices and the development of Next-Generation Factor XIa Inhibitors. Clinicians are increasingly adopting Left Atrial Appendage Closure Devices for non-pharmacological stroke prevention, particularly for high-risk patients prone to bleeding complications, moving away from long-term oral anticoagulation. This shift has led manufacturers to innovate with safer, more effective devices, accelerating adoption, as seen in Boston Scientific's Watchman franchise, which grew by 28.4% in Q2 2025. Concurrently, Next-Generation Factor XIa Inhibitors are emerging as a transformative pharmaceutical trend. These novel therapeutics promise to enhance stroke prophylaxis by preventing clot formation without impairing natural hemostasis, thereby significantly reducing major bleeding events—a critical safety concern with existing anticoagulants. For instance, the Factor XI inhibitor abelacimab demonstrated a 62% reduction in bleeding events compared to rivaroxaban, indicating its substantial clinical potential.
Key Market Players
* Parexel International Corporation
* AtriCure Inc.
* Boehringer Ingelheim GmbH
* Boston Scientific Corporation
* Bristol- Myers Squibb Corporation
* Cardio Focus Inc.
* Sanofi S.A.
* Biosense Webster Inc.
* Endoscopic Technologies Inc.
* Abbott Laboratories
* Johnsons & Johnson Services, Inc.
Report Scope
In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Atrial Fibrillation Market, By Treatment Type
* Pharmacological Treatment
* Non-Pharmacological Treatment
# Atrial Fibrillation Market, By End-use
* Hospital
* Specialty Clinics
* Others
# Atrial Fibrillation Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.
Available Customizations:
Global Atrial Fibrillation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Atrial Fibrillation Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion))
5.2.2. By End-use (Hospital, Specialty Clinics, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Atrial Fibrillation Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By End-use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Atrial Fibrillation Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By End-use
6.3.2. Canada Atrial Fibrillation Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By End-use
6.3.3. Mexico Atrial Fibrillation Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By End-use
7. Europe Atrial Fibrillation Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By End-use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Atrial Fibrillation Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By End-use
7.3.2. France Atrial Fibrillation Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By End-use
7.3.3. United Kingdom Atrial Fibrillation Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By End-use
7.3.4. Italy Atrial Fibrillation Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By End-use
7.3.5. Spain Atrial Fibrillation Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By End-use
8. Asia Pacific Atrial Fibrillation Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By End-use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Atrial Fibrillation Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By End-use
8.3.2. India Atrial Fibrillation Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By End-use
8.3.3. Japan Atrial Fibrillation Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By End-use
8.3.4. South Korea Atrial Fibrillation Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By End-use
8.3.5. Australia Atrial Fibrillation Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By End-use
9. Middle East & Africa Atrial Fibrillation Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By End-use
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Atrial Fibrillation Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By End-use
9.3.2. UAE Atrial Fibrillation Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By End-use
9.3.3. South Africa Atrial Fibrillation Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By End-use
10. South America Atrial Fibrillation Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By End-use
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Atrial Fibrillation Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By End-use
10.3.2. Colombia Atrial Fibrillation Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By End-use
10.3.3. Argentina Atrial Fibrillation Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By End-use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Atrial Fibrillation Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Parexel International Corporation
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. AtriCure Inc.
15.3. Boehringer Ingelheim GmbH
15.4. Boston Scientific Corporation
15.5. Bristol- Myers Squibb Corporation
15.6. Cardio Focus Inc.
15.7. Sanofi S.A.
15.8. Biosense Webster Inc.
15.9. Endoscopic Technologies Inc.
15.10. Abbott Laboratories
15.11. Johnsons & Johnson Services, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們